28 Sep 2016 07:00
Tissue Regenix Group plc
Notice of Interim Results
Leeds, 28 September 2016 - Tissue Regenix Group (AIM:TRX) ("Tissue Regenix" or "The Group") the regenerative medical devices company today gives notice that it will announce its interim results for the six months ending 31 July 2016, on Wednesday 12th October.
For more Information:
Tissue Regenix Group plc Caitlin Pearson Corporate Communications Officer
| Tel: 0330 430 3073 |
Jefferies International Ltd Simon Hardy / Harry Nicholas
| Tel: 020 7029 8000
|
About Tissue Regenix
Tissue Regenix is a leading medical devices company in the field of regenerative medicine. The company's patented decellularisation ('dCELL®') technology removes DNA and other cellular material from animal and human tissue leaving an acellular tissue scaffold which is not rejected by the patient's body which can then be used to repair diseased or worn out body parts. The potential applications of this process are diverse and address many critical clinical needs such as vascular disease, heart valve replacement and knee repair.
Tissue Regenix was formed in 2006 when it was spun-out from the University of Leeds. The company commercialises academic research conducted by our partners around the World.
In November 2012 Tissue Regenix Group plc set up a subsidiary company in the United States - 'Tissue Regenix Wound Care Inc.', as part of its commercialisation strategy for its dCELL® technology platform.
Tissue Regenix Group (TRX)